This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Publication Indicates That MultiStem Treatment May Reduce Inflammation And Promote Reparative Processes Following Acute Brain Injury

CLEVELAND, Oct. 10, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the publication of an article in the peer-reviewed scientific journal, Journal of Neuroinflammation, that describes the results of a preclinical study evaluating the administration of MultiStem ® cell therapy for the treatment of traumatic brain injury (TBI) in rodents. The article, authored by investigators from The University of Texas Health Science Center at Houston (UTHealth), together with scientists from Athersys, describes preclinical study results demonstrating that administration of MultiStem cells modulates the inflammatory environment that follows TBI, by reducing immune cell and cytokine activity associated with inflammation.

TBI affects approximately 1.7 million patients in the United States annually and severe injuries can be associated with significant long-term physical, cognitive and psychological deficits.  As in other acute injuries and diseases affecting the central nervous system, such as stroke and spinal cord injury, TBI leads to substantial inflammation, which slows innate recovery processes and contributes to secondary tissue damage.

The publication further illustrates the mechanisms through which cellular therapy may provide benefit to patients suffering significant injury to the central nervous system. "MultiStem therapy shows promise for treating traumatic brain injury, as well as ischemic stroke and spinal cord injury," said Dr. Robert Mays, Head of Neuroscience at Athersys.  "These latest preclinical results further confirm that MultiStem cells have substantial anti-inflammatory and immunomodulatory properties that could be important in treating multiple central nervous system disease conditions."

In pre-clinical experiments, rodents underwent controlled cortical impact brain injury receiving either MultiStem cells or placebo following the injury. The injured, cell-treated animals had significant increases in T-regulatory cells in the spleen and plasma at 24 and 48 hours, respectively, compared to the placebo-treated animals. Further, MultiStem treatment was associated with an increase in the ratio of neuroprotective (M2) macrophages relative to proinflammatory (M1) macrophages responsible for the production of inflammatory cytokines and associated neurotoxicity.  Additionally, cell treatment resulted in a reduction of blood brain barrier permeability and preserved splenic mass following the injury, suggesting that MultiStem treatment may provide benefit to TBI patients through multiple pathways.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,099.76 +75.70 0.42%
S&P 500 2,117.24 +8.95 0.42%
NASDAQ 5,028.6190 +23.2280 0.46%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs